Sign In
Buy LYEL
$12.57
-2.32 (-15.58%)
At Close: Jun 03, 2026
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
08:00am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
04:03am, Wednesday, 27'th May 2026
Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session modera
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
12:20am, Saturday, 23'rd May 2026
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
07:10pm, Friday, 22'nd May 2026
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)
10:36am, Tuesday, 19'th May 2026
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Lyell Immunopharma Announces Participation in May Investor Conferences
08:00am, Tuesday, 12'th May 2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
04:05pm, Wednesday, 06'th May 2026
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Increase in Short Interest
03:39am, Sunday, 19'th Apr 2026
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 1,138,296 shares,
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
01:41am, Friday, 17'th Apr 2026
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 07'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX)
01:24am, Monday, 06'th Apr 2026
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lyell Immunopharma (NASDAQ: LYEL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the tw
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet
04:37pm, Monday, 23'rd Mar 2026
Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
04:05pm, Thursday, 12'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor
Market Today: Oil Swings, Oracle Pops; Meta Buys Bot Network
05:35pm, Tuesday, 10'th Mar 2026
Stock News U.S. pump prices jump on war-driven supply shock: Average U.S. gasoline rose to about $3.54/gal, the highest since midâ2024, as the U.S.âIran con
First Look: Oil Swings, Live Nation Deal, EV & eVTOL Moves
07:38am, Tuesday, 10'th Mar 2026
Stock News Oil pulls back from $100+: Brent fell roughly 8% toward $91 as President Trump indicated the Iran conflict could end âvery soon,â while Saudi Ara
